Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Gross Margin (2018 - 2025)

10x Genomics' Gross Margin history spans 8 years, with the latest figure at 68.09% for Q4 2025.

  • For Q4 2025, Gross Margin rose 85.0% year-over-year to 68.09%; the TTM value through Dec 2025 reached 69.05%, up 119.0%, while the annual FY2025 figure was 69.05%, 119.0% up from the prior year.
  • Gross Margin for Q4 2025 was 68.09% at 10x Genomics, up from 67.32% in the prior quarter.
  • Across five years, Gross Margin topped out at 95.76% in Q2 2021 and bottomed at 62.18% in Q3 2023.
  • The 5-year median for Gross Margin is 71.25% (2025), against an average of 73.05%.
  • The largest annual shift saw Gross Margin soared 1919bps in 2021 before it tumbled -1993bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 80.77% in 2021, then fell by -5bps to 76.43% in 2022, then fell by -18bps to 62.93% in 2023, then increased by 7bps to 67.24% in 2024, then rose by 1bps to 68.09% in 2025.
  • Per Business Quant, the three most recent readings for TXG's Gross Margin are 68.09% (Q4 2025), 67.32% (Q3 2025), and 72.34% (Q2 2025).